Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$628M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$567M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$392M |
| 5 |
Walmart Inc
WMT
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$451M |
| 2 |
PepsiCo
PEP
|
+$382M |
| 3 |
Philip Morris
PM
|
+$256M |
| 4 |
Roku
ROKU
|
+$252M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.34% |
| 2 | Technology | 12.68% |
| 3 | Consumer Discretionary | 10.4% |
| 4 | Financials | 10.32% |
| 5 | Consumer Staples | 8.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Champions Oncology
CSBR
$69.5M
| $1.05M | ﹤0.01% |
185,046
+4,400
| +2% | +$28.5K |
|
|
PHLT
2577
DELISTED
Performant Healthcare Inc
PHLT
| $1.05M | ﹤0.01% |
950,739
+5,900
| +0.6% | +$6.94K |
|
2578
BBVA Argentina
BBAR
$3.17B
| $1.04M | ﹤0.01% |
+239,864
| New | +$1.87M |
|
2579
Moleculin Biotech
MBRX
$4.49M
| $1.04M | ﹤0.01% |
416
+45
| +12% | +$116K |
|
2580
Digital Turbine
APPS
$1.55B
| $1.04M | ﹤0.01% |
160,900
+149,300
| +1,287% | +$927K |
|
2581
Watsco Inc
WSO
$12.8B
| $1.03M | ﹤0.01% |
6,100
-10,477
| -63% | -$1.7M |
|
|
ALO
2582
DELISTED
Alio Gold Inc
ALO
| $1.03M | ﹤0.01% |
1,665,789
+176,436
| +12% | +$135K |
|
2583
RBB Bancorp
RBB
$465M
| $1.03M | ﹤0.01% |
52,200
+15,900
| +44% | +$304K |
|
|
SRRA
2584
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.03M | ﹤0.01% |
65,794
+7,978
| +14% | +$153K |
|
|
FLNA
2585
Filana Therapeutics
FLNA
$44.1M
| $1.02M | ﹤0.01% |
851,958
+169,166
| +25% | +$217K |
|
2586
Direxion Daily Financial Bull 3x ETF
FAS
$2.5B
| $1.02M | ﹤0.01% |
+13,100
| New | +$993K |
|
2587
Lisata Therapeutics
LSTA
$9.73M
| $1.01M | ﹤0.01% |
26,123
+767
| +3% | +$29.8K |
|
|
GVP
2588
DELISTED
GSE Systems, Inc.
GVP
| $1.01M | ﹤0.01% |
57,726
-190
| -0.3% | -$3.8K |
|
2589
Tecnoglass Holdings Inc.
TGLS
$1.86B
| $1.01M | ﹤0.01% |
124,136
-18,985
| -13% | -$139K |
|
2590
Matrix Service
MTRX
$332M
| $1.01M | ﹤0.01% |
+58,759
| New | +$1.11M |
|
|
DPLO
2591
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $1M | ﹤0.01% |
204,900
+58,100
| +40% | +$325K |
|
|
PACD
2592
DELISTED
Pacific Drilling S.A. Common Shares
PACD
| $1M | ﹤0.01% |
255,700
+178,900
| +233% | +$1.26M |
|
2593
Tenet Healthcare
THC
$21.5B
| $997K | ﹤0.01% |
+45,075
| New | +$960K |
|
|
ECOL
2594
DELISTED
US Ecology, Inc.
ECOL
| $997K | ﹤0.01% |
15,600
-49,053
| -76% | -$3.03M |
|
2595
Vanguard Mortgage-Backed Securities ETF
VMBS
$15.6B
| $995K | ﹤0.01% |
+18,675
| New | +$990K |
|
2596
iShares MSCI China ETF
MCHI
$6.16B
| $993K | ﹤0.01% |
+17,700
| New | +$1.02M |
|
|
IFLN
2597
Invesco Bloomberg Enhanced Fallen Angels ETF
IFLN
$307M
| $991K | ﹤0.01% |
52,094
+14,253
| +38% | +$271K |
|
|
RDGT
2598
Ridgetech Inc
RDGT
$3.03M
| $991K | ﹤0.01% |
23
| – | – |
|
2599
Retractable Technologies
RVP
$20.7M
| $990K | ﹤0.01% |
861,242
+56,204
| +7% | +$44.9K |
|
|
PSB
2600
DELISTED
PS Business Parks, Inc.
PSB
| $985K | ﹤0.01% |
5,412
-17,788
| -77% | -$3.14M |
|
Similar funds
Jim Simons's Q3 2019 Portfolio in Review
As of Q3 2019, Jim Simons held 3,920 positions worth $118B, up 4% from $114B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons deployed $5.29B of net new capital in Q3 2019, opening 406 new positions and adding to 1,848 existing holdings. Its largest new stake was UnitedHealth: 1,624,826 shares worth $353M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $451M trimmed.
- Jim Simons's largest Q3 2019 buy was UnitedHealth: 1,624,826 shares worth $353M.
- Jim Simons added most to Celgene Corp in Q3 2019, an estimated $628M increase.
- Jim Simons's biggest Q3 2019 reduction was Apple, cutting an estimated $451M.
- Jim Simons fully exited Red Hat Inc in Q3 2019, selling an estimated $248M.
- Jim Simons's ten largest holdings make up 11% of its $118B portfolio in Q3 2019.
- Jim Simons opened 406 new positions and closed 522 in Q3 2019.
- Jim Simons's portfolio value rose 4% quarter-over-quarter to $118B.
Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.